^
Association details:
| Biomarker: | ALK positive + EML4-ALK fusion + TP53 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Regimen: | (Avastin (bevacizumab) + carboplatin + paclitaxel + Tecentriq (atezolizumab)) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report
Published date:
06/23/2023
Excerpt:
We report the case of a 42-year-old male patient with ALK-positive lung adenocarcinoma...Biopsy of the liver metastases revealed echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) fusion and tumor protein p53 (TP53) mutation...the patient exhibited a remarkable clinical response to treatment with a combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP).
DOI:
https://doi.org/10.2147/OTT.S404035
